Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 14/20 | 0.40 |
| ▸ | HTR2B | P41595 | 13/20 | 0.40 |
| ▸ | HTR2A | P28223 | 8/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17942003 | 1.00 | HRH3 (0.46) | HRH3HRH4HTR2CHTR2BHTR2A | |
| SCHEMBL17942047 | 0.81 | ADRA1A (0.40) | HTR2BADRA1A | |
| SCHEMBL17942046 | 0.81 | ADRA1A (0.40) | HTR2BADRA1A | |
| SCHEMBL17950209 | 0.77 | ADRA1A (0.39) | ADRA1A | |
| SCHEMBL21573830 | 0.77 | NAMPT (0.38) | ADRA1A | |
| SCHEMBL17942056 | 0.73 | NAMPT (0.44) | HTR2BADRA1A | |
| SCHEMBL19764579 | 0.69 | NAMPT (0.43) | — | |
| SCHEMBL3394059 | 0.69 | ADRA1A (0.59) | HTR2BADRA1A | |
| SCHEMBL19764580 | 0.68 | ADRA1A (0.41) | HTR2BADRA1A | |
| SCHEMBL17950210 | 0.67 | ADRA1A (0.52) | HTR2BADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3247705-B1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF AS NAMPT INHIBITORS | MILLENNIUM PHARM INC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-10323018-B2 | Quinazoline and quinoline compounds and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20180009784-A1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2018-01-11 | — | — | US | disclosed |
| EP-3247705-A1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2017-11-29 | — | — | EP | disclosed |
| WO-2016118565-A1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-07-28 | — | — | WO | disclosed |
| WO-2016118565-A1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323018-B2 | Quinazoline and quinoline compounds and uses thereof | NAMPT, NQO2, NNMT | HRH3 41/4885HRH4 48/4885HTR2C 3198/4885 |
| US-20180009784-A1 | QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF | NAMPT, NQO2, NNMT | HRH3 41/4885HRH4 48/4885HTR2C 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.